{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:36:28Z","timestamp":1793136988558,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jaip.2025.07.046","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T06:56:13Z","timestamp":1754549773000},"page":"3011-3020.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and Safety of Tezepelumab in Adults With Severe, Uncontrolled Asthma in Asia: Results From the Phase 3 DIRECTION Study"],"prefix":"10.1016","volume":"13","author":[{"given":"Xinyan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kewu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli John","family":"Berame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae-Sim","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyi (Chloe)","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiju (Wendy)","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Domek-Zielinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harbans","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nestor A.","family":"Molfino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhia S.","family":"Ponnarambil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanshan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2025.07.046_bib2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(19)31147-X","article-title":"Prevalence, risk factors, and management of asthma in China: a national cross-sectional study","volume":"394","author":"Huang","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.07.046_bib3","first-page":"917","article-title":"A cross-section study of severe asthma in eight provinces of China [in Chinese]","volume":"55","author":"Su","year":"2016","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.1016\/j.jaip.2025.07.046_bib4","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-2600(23)00180-7","article-title":"Asthma care for all: lessons from the Philippines","volume":"11","author":"Ho","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.07.046_bib5","doi-asserted-by":"crossref","first-page":"467","DOI":"10.4168\/aair.2020.12.3.467","article-title":"Increasing prevalence and mortality of asthma with age in Korea, 2002-2015: a nationwide, population-based study","volume":"12","author":"Lee","year":"2020","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaip.2025.07.046_bib6","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1186\/s12890-023-02685-0","article-title":"Medical resource utilization and the associated costs of asthma in China: a 1-year retrospective study","volume":"23","author":"Yang","year":"2023","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jaip.2025.07.046_bib7","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/1010539520920524","article-title":"Socioeconomic burden of disease due to asthma in South Korea","volume":"32","author":"Lee","year":"2020","journal-title":"Asia Pac J Public Health"},{"key":"10.1016\/j.jaip.2025.07.046_bib8","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1164\/ajrccm.164.supplement_1.2103026","article-title":"Anti-immunoglobulin E (omalizumab) therapy in allergic asthma","volume":"164","author":"Busse","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.07.046_bib9","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","article-title":"Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study","volume":"2","author":"Castro","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.07.046_bib10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4168\/aair.2016.8.4.319","article-title":"Omalizumab improves quality of life and asthma control in Chinese patients with moderate to severe asthma: a randomized phase III study","volume":"8","author":"Li","year":"2016","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaip.2025.07.046_bib11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2147\/JAA.S406628","article-title":"Real-world safety and effectiveness of omalizumab in moderate to severe allergic asthma patients in China: a post-authorization study","volume":"16","author":"Su","year":"2023","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaip.2025.07.046_bib12","doi-asserted-by":"crossref","first-page":"00750","DOI":"10.1183\/23120541.00750-2023","article-title":"Efficacy and safety of mepolizumab in a Chinese population with severe asthma: a phase III, randomised, double-blind, placebo-controlled trial","volume":"10","author":"Chen","year":"2024","journal-title":"ERJ Open Res"},{"issue":"Suppl 67","key":"10.1016\/j.jaip.2025.07.046_bib13","article-title":"Dupilumab in Asia-Pacific patients with persistent asthma","volume":"62","author":"Zhang","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2025.07.046_bib14","article-title":"Benralizumab efficacy and safety in severe asthma: a randomized trial in Asia","volume":"1","author":"Lai","year":"2024","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2025.07.046_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2019.105806","article-title":"Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma","volume":"159","author":"Albers","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2025.07.046_bib20","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.07.046_bib21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","article-title":"Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies","volume":"6","author":"FitzGerald","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.07.046_bib22","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.07.046_bib23","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.21037\/jtd.2017.04.74","article-title":"Severe and uncontrolled asthma in China: a cross-sectional survey from the Australasian Severe Asthma Network","volume":"9","author":"Wang","year":"2017","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jaip.2025.07.046_bib24","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1186\/s12890-021-01722-0","article-title":"Distribution of inflammatory phenotypes among patients with asthma in Jilin Province, China: a cross-sectional study","volume":"21","author":"Shi","year":"2021","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jaip.2025.07.046_bib25","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/14728222.2020.1783242","article-title":"Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma","volume":"24","author":"Gauvreau","year":"2020","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.jaip.2025.07.046_bib26","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.07.046_bib27","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.07.046_bib31","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.rmed.2005.08.012","article-title":"Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire","volume":"100","author":"Juniper","year":"2006","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2025.07.046_bib32","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaci.2011.12.986","article-title":"Asthma outcomes: pulmonary physiology","volume":"129","author":"Tepper","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.07.046_bib33","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0895-4356(94)90036-1","article-title":"Determining a minimal important change in a disease-specific Quality of Life Questionnaire","volume":"47","author":"Juniper","year":"1994","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaip.2025.07.046_bib34","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaip.2015.07.008","article-title":"Psychometric properties of the Asthma Symptom Diary (ASD), a diary for use in clinical trials of persistent asthma","volume":"4","author":"Globe","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.07.046_bib35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s41687-019-0109-2","article-title":"Evaluating minimal important differences and responder definitions for the asthma symptom diary in patients with moderate to severe asthma","volume":"3","author":"Globe","year":"2019","journal-title":"J Patient Rep Outcomes"},{"key":"10.1016\/j.jaip.2025.07.046_bib36","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.07.046_bib37","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.07.046_bib38","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.07.046_bib39","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.07.046_bib40","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jaip.2018.01.025","article-title":"Inhaled corticosteroids safety and adverse effects in patients with asthma","volume":"6","author":"Heffler","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.07.046_bib41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1164\/rccm.202210-2005OC","article-title":"Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials","volume":"208","author":"Corren","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.07.046_bib42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12940-020-0563-6","article-title":"Association between exposure to traffic-related air pollution and pediatric allergic diseases based on modeled air pollution concentrations and traffic measures in Seoul, Korea: a comparative analysis","volume":"19","author":"Min","year":"2020","journal-title":"Environ Health"},{"key":"10.1016\/j.jaip.2025.07.046_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2023.117860","article-title":"Analysis of PM(2.5) inorganic and organic constituents to resolve contributing sources in Seoul, South Korea and Beijing, China and their possible associations with cytokine IL-8","volume":"243","author":"Park","year":"2024","journal-title":"Environ Res"},{"key":"10.1016\/j.jaip.2025.07.046_bib44","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jaci.2011.11.031","article-title":"Roles of pollution in the prevalence and exacerbations of allergic diseases in Asia","volume":"129","author":"Leung","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.07.046_bib45","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jaci.2017.09.008","article-title":"Changing trends and challenges in the management of asthma in Asia","volume":"140","author":"Song","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.07.046_bib46","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2213-2600(22)00492-1","article-title":"Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study","volume":"11","author":"Menzies-Gow","year":"2023","journal-title":"Lancet Respir Med"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825007573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825007573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T12:06:04Z","timestamp":1774958764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219825007573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2213219825007573"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2025.07.046","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Tezepelumab in Adults With Severe, Uncontrolled Asthma in Asia: Results From the Phase 3 DIRECTION Study","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2025.07.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}